Zhou Lab

1915

Citations

20

h-index

About the Lab

Our Team

Dr. Zhou is a physician-scientist specializing in cancer immunology, cancer biology, and hematopoietic cell therapy. The Zhou lab develops model systems using genetically engineered mouse models, patient-derived xenografts, ex vivo immune cell differentiation and expansion, tumor organoids, organoid-fibroblast co-cultures, and advanced techniques in single-cell transcriptomics, immune phenotyping, and spatial analysis. These approaches are applied to research in stem cell therapy, cancer biology, and cancer immune responses. Current research in Dr. Zhou’s lab includes projects focused on the molecular mechanisms of pancreatic cancer biomarkers in cancer progression and therapy resistance (CA294584), the role of Notch signaling in hematopoietic stem cell (HSC) niche development following bone marrow transplantation (HL103827), and the study of colon epithelial homeostasis, immunity, and carcinogenesis (CA222064). Dr. Zhou is board certified in Clinical Pathology, Transfusion Medicine, and Molecular Genomic Pathology.

Our Team

Lan Zhou, PhD, MD
Professor of Pathology and Laboratory Medicine, Academic Institute
Member, Research Institute, Academic Institute
Vice-Chair for Research, Department of Pathology & Genomic Medicine


Dr. Bingqing Zou, Postdoctoral Fellow II
Dr. Mofei Huang, Postdoctoral Fellow III 
Yimin Ma, Research Assistant I

 

Pathology News
There’s a New Strep in Town
New study highlights the complexity of human infections caused by a rapidly emerging strep subtype
Improving Vaccine Design with an AI Booster

CEPI awards $34 million to the Houston Methodist Research Institute-led consortium to use artificial intelligence for the design of vaccines to fight diseases with pandemic potential.

Omicron – Ongoing Lessons in a Pandemic

Omicron Demonstrates the Power and Necessity of Genetic Sequencing in a Pandemic

Researchers Uncover Distinct Patterns of a Common Pathology in Dementia

Known as LATE, a very common form of brain pathology affects ~40% of elderly patients. Researchers at Houston Methodist have unraveled several patterns of LATE in the brains of aging and demented patients. These patterns have distinct clinical, pathologic and genetic associations.

Fighting a Deadly Duo
Investigating therapeutics to fight deadly TB/HIV coinfections.
Houston Methodist and Purdue University Make a Breakthrough That May Result in a More Effective Tuberculosis Vaccine

A recombinant bovine adenoviral mucosal vaccine expressing mycobacterial antigen-85B generates robust protection against tuberculosis in mice

Explore the following:

Donate to Houston Methodist

With your support, Houston Methodist provides exceptional research, education, and care that is truly leading medicine.

Donate Now